FilingSEC EDGAR10-Q
Aprea Therapeutics Receives Nasdaq Compliance Extension Until January 2027
· SEC accepted
StageCompliance Extension
Filing content
The company has been granted an additional 180-day period until January 19, 2027, to regain compliance with Nasdaq's minimum bid price requirement.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…